Loading company…
Riskpilot
← Back to search
Sign in
Get full access
ALICE PHARMA AS
AS
Active
Org 921176104
Annen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk · NACE 72190
Est. 2018
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2019
NOK 0
EBITDA margin
—
+99% vs 2018
Equity ratio
51.0%
Financial strength
Net profit 2019
NOK -169
+99% vs 2018
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2018
0M
0%
2019
Key figures
Annual report 2019
Revenue
NOK 0
—
EBITDA
NOK -167
+99%
Net profit
NOK -169
+99%
Total assets
NOK 30K
-1%
Equity
NOK 15K
-1%
Employees
0
—
Company information
Legal name
ALICE PHARMA AS
Org number
921176104
Legal form
Aksjeselskap
NACE code
72190 · Annen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk
Founded
18. juli 2018
Share capital
NOK 3 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder hver for seg.
Company purpose
Forskning og utvikling av ny medisin og hva som dermed står i forbindelse, herunder også deltagelse i andre selskap.
Contact
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Annen forskning og annet utviklingsarbeid innen naturvitenskap og teknikk
Companies in
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
Income statement
NOK thousands
Item
2018
2019
Revenue
0
0
Staff expenses
−0
−0
EBITDA
−15
−0
Depreciation & amort.
−0
−0
EBIT
−15
−0
Net financials
0
−0
Profit before tax
−15
−0
Tax
−0
−0
Net profit
−15
−0
Balance sheet
NOK thousands
Item
2018
2019
Total assets
30
30
Equity
15
15
Long-term debt
0
0
Short-term debt
15
15
Total debt
15
15
Financial ratios
5-year trend
EBITDA margin
-16700.0%
This company
15.8%
Market median
-105796% vs market
2018
2019
Equity ratio
51.0%
This company
38.2%
Market median
+34% vs market
2018
2019
Return on equity
-1.1%
This company
18.4%
Market median
-106% vs market
2018
2019
Net profit margin
-16900.0%
This company
8.1%
Market median
-208742% vs market
2018
2019
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2018
2019
Debt / equity
0.96×
This company
0.62×
Market median
+55% vs market
2018
2019
Annual reports & filings
Annual report 2019
Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
RP
Rolv Petter Thorkildsen
Chief Executive Officer
Chief Executive Officer
2018
Board of directors
Non-executive oversight
Name
Role
Member since
Former (1)
ES
Eivind Stoud Platou Semb
Chairman
2021 – 2021
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of ALICE PHARMA AS also hold positions in
0
other companies.
Person
Role here
Other companies
Rolv Petter Thorkildsen
Chief Executive Officer
0 companies
Eivind Stoud Platou Semb
Chairman
0 companies